Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Receives Japanese Patent for UNIclone Technology

Premium

German diagnostics company Protagen said this week that it has received a Japanese patent for a method of identifying and selecting clones based on its UNIclone technology platform.

The UNIclone platform, which Protagen has licensed from Berlin's Max-Planck Institute, consists of libraries of human recombinant proteins representing more than 10,000 human genes. It is designed for use with the company's UNIarray companion diagnostic and UNIchip antibody profiling platform.

The company also possesses a European patent for the technology.

This June, Protagen signed a cooperation contract with Bayer Schering Pharma AG for the discovery of novel biomarkers in endometriosis using its UNIarray device, which uses proteins generated by the UNIclone platform (PM 06/11/2010).

In July it announced a partnership with Mikrogen to use the UNIarray platform for the discovery of autoantibody signatures associated with infectious diseases (PM 07/09/2010).

Last August the company received €3.7 million ($5.3 million) in funding to expand its work developing biomarkers for diseases including multiple sclerosis and prostate cancer.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.